More tools:Markets·Screener·Research·Chat

Clearmind Medicine Inc. Common Shares (CMND) Financial Statements

Clearmind Medicine Inc. Common Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00KWY2X19
XNAS · usd
1.03▼ 0.13 (-11.21%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.16
Day's Range0.92 – 1.15
52-Week Range0.07 – 4.66
Volume2.4M
Avg Volume723.4K
Share Statistics
Shares Outstanding
Employees2
ExchangeXNAS
Listed2021-08-10
Share count as of January 19, 2026
Loading Income Statement…
Key questions about Clearmind Medicine Inc. Common Shares (CMND)
What is Clearmind Medicine Inc. Common Shares's Market Cap?
Clearmind Medicine Inc. Common Shares's Market Cap is $162.8K, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Enterprise Value?
Clearmind Medicine Inc. Common Shares's Enterprise Value is -$9.1M, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Net Income (TTM)?
Clearmind Medicine Inc. Common Shares's Net Income (TTM) is -$6.6M, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Diluted EPS (TTM)?
Clearmind Medicine Inc. Common Shares's Diluted EPS (TTM) is -42.00, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Net Debt?
Clearmind Medicine Inc. Common Shares's Net Debt is -$9.3M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemOct 31, 2025Oct 31, 2024Oct 31, 2023Oct 31, 2022Oct 31, 2021Oct 31, 2020
Operating expenses
General and administrative (Note 17)—
Research and development, net (Note 18)—
Total operating expenses—
Finance income (expenses)
Changes in fair value of derivative warrant liabilities (Notes 7, 8e (iii))—
Changes in fair value of short-term investments Note 5)—
Foreign exchange loss—
Other finance expenses—
Total finance income (expenses)—
Other income
Loss Before taxes—
Tax expenses—
Net Loss